1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential

Report Details
Ovarian Cancer Therapies – Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities
What’s the future for treating cancer of the human ovaries? Visiongain’s new study forecasts those pharmaceutical revenues. There you find outlooks for sales growth in that industry. You also explore trends, results, treatments, R&D, and opportunities, seeing prospects.

Our report gives revenue predictions to 2025 at overall world market, submarket, product and national level. So avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and results are possible for those cancer treatments.

Read on, then, to explore ovarian cancer therapy and see what future revenues that pharma market could generate.

Forecasts and other analysis to benefit your research, assessments, plans and decisions
With our new study you explore prospects for companies developing, producing and marketing drugs for treating cancer of the ovaries. See present trends and future possibilities.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Assess research and development too, seeing prospects. Also get 57 tables, 57 charts and three interviews with companies.

So avoid missing out on original data and discussions to help your work.

Treating ovarian tumours – find R&D and sales growth opportunities, helping your work
Our study’s purpose is to help your research, analyses and decisions on those therapies, also benefiting your authority and reputation for insight.

The future holds high promise for organisations treating that gynaecological disorder. Discover the progress and gains possible there, avoiding struggles to find business information you need. See how patients, healthcare providers and companies can benefit.

Visiongain’s analysis finds the ovarian cancer treatments market evolves, as new drugs enter the market and promising R&D pipeline candidates reach late-stage clinical trials. Discover what revenues are possible from 2015 in that expanding pharma segment.

Opportunities for pharmaceutical companies open there, giving high sales potentials. Our new study finds that market can achieve strong revenue growth from 2015 to 2025, driven by expanding patient populations and revenues from recent and expected product launches.

Though no such study covers everything, the following sections show how our new investigation benefits your work.

Forecasting that world market and sub-segments for treating ovarian cancer
What are the secrets of that technology's progress? And what potential does it have? Find in our report overall world revenue to 2025 for those antineoplastic medicines – existing, emerging and expected drugs.

Also explore individual revenue predictions to 2025 for four therapeutic submarkets at world level:
- Chemotherapy
- Targeted therapies
- Immunotherapy
- Hormonal treatments.

Where lie the best sales potentials? With our analysis you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors’ actions and prospects.

See how those cancer-treating medicines develop, hearing where needs and business opportunities exist. With a growing incidence of ovarian cancer and high recurrence and mortality rates, the demand for better treatments will continue to bolster that drug market.

You also find sales predictions by product, exploring how they can succeed.

Predictions of leading products’ sales – what’s possible for those cancer-treating drugs?
How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts ovarian cancer treatment revenues of these three brands:
- Avastin (bevacizumab)
- Lynparza (olaparib).
- Yondelis (trabectedin).

There y

Table Of Contents

Ovarian Cancer Drug Therapy: Companies, RandD and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential
Table of Contents
1. Report Overview
1.1 Overview of the World Market for Ovarian Cancer Treatment
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
1.10 Abbreviations Frequently Used in This Report

2. An Introduction to Ovarian Cancer Therapy
2.1 Overview of Ovarian Cancer
2.1.1 Symptoms of Ovarian Cancer
2.1.2 Risk Factors for Ovarian Cancer
2.1.3 Global Prevalence and Incidence of Ovarian Cancer
2.2 Diagnosing Ovarian Cancer
2.2.1 Laboratory Testing: The Uncertainty of CA 125 Testing
2.2.2 The Potential of Lysophosphatidic Acid Assay for Early Stage Ovarian Cancer
2.2.3 Imaging Studies for Diagnosing Ovarian Cancer
2.3 Treatment Options for Cancer
2.3.1 Chemotherapy
2.3.2 Targeted Therapy
2.3.3 Immunotherapy: Fastest Growing Sector in Cancer Therapy
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Hormone Therapy
2.3.5 First-Line Therapy: Platinum-Taxane Treatment
2.3.6 Second-Line Therapy
2.3.7 Maintenance Therapy

3. Ovarian Cancer: World Market 2015-2025
3.1 Ovarian Cancer Therapies Market, 2014
3.1.1 A Note on Monoclonal Antibodies in this Report
3.2 Ovarian Cancer Therapies Market Forecast, 2015-2025
3.3 Driving and Restraining Forces Affecting the Ovarian Cancer Therapy Market
3.3.1 Increasing Patient Population
3.3.2 Intense Competition from Generics
3.4 The Ovarian Cancer Therapy Submarket Shares, 2019 and 2025
3.5 The Future of the World Market for Ovarian Cancer Therapy by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025
3.5.1 Targeted Therapy—Leading Submarket in Ovarian Cancer Therapy by 2025
3.5.2 Chemotherapy—Remains First-Line Treatment for Ovarian Cancer
3.5.3 Immunotherapy—The Fastest Growing Segment in Cancer Therapy
3.5.4 Hormone Therapy—Rare Treatment in Ovarian Cancer

4. Leading Ovarian Cancer Drugs 2014
4.1 Avastin (Roche/Chugai) - The World Market Leader
4.1.1 Avastin Revenue, 2010-2014 - Mixed Growth
4.1.2 Avastin Ovarian Cancer Forecast, 2015-2025
4.2 Lynparza (AstraZeneca)
4.2.1 Lynparza Forecast 2015-2025
4.3 Yondelis (Zeltia/Johnson and Johnson)
4.3.1 Yondelis (Zeltia/Johnson and Johnson): Historical Revenues
4.3.2 Yondelis Forecast 2015-2025
4.4 Other Ovarian Cancer Therapies

5. Leading Regional and National Markets in the Ovarian Cancer Therapy 2015-2025
5.1 Regional Breakdown of the World Ovarian Cancer Therapeutics Market
5.1.1 How Will Regional Market Shares Change to 2025?
5.2 The US Ovarian Cancer Drug Therapy Market, 2014
5.2.1 US Ovarian Cancer Therapeutics Market Forecast, 2015-2025
5.3 The Ovarian Cancer Therapy Market in the EU5 Markets to 2025
5.3.1 German Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.2 French Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.3 UK: Pharmaceutical Price Regulation Scheme and Market Forecast, 2015-2025
5.3.3.1 NICE: Guidance for Ovarian Cancer Therapies
5.3.4 Spanish Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.5 Italian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.4 Japan: Growth in Generics - Ovarian Cancer Therapy Market Forecast, 2015-2025
5.5 Chinese Ovarian Cancer Therapy Market Forecast, 2015-2025
5.6 Indian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.7 Brazilian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.8 Russian Ovarian Cancer Therapy Market Forecast, 2015-2025

6. Leading Companies in the Ovarian Cancer Therapy Market
6.1 Companies with Exclusivity in 2014
6.2 Johnson and Johnson (JandJ)
6.2.1 Sales and Performance Analysis, 2014
6.2.2 Pharmaceutical Segment Sales Analysis, 2014
6.2.2.1 RandD Performance Analysis, 2014
6.2.3 Recent MandA Activity: JandJ Acquires Alios BioPharma and Aragon Pharmaceuticals
6.3 Roche
6.3.1 Sales and Performance Analysis, 2014
6.3.2 Pharmaceutical Segment Sales Analysis, 2014
6.3.2.1 Cancer Drug Sales and Performance Analysis, 2014
6.3.2.2 Pharmaceutical Segment RandD Performance Analysis, 2014
6.3.3 Recent MandA Activity
6.4 AstraZeneca
6.4.1 Sales and Performance Analysis, 2014
6.4.2 Pharmaceutical Segment Sales Analysis, 2014
6.4.2.1 Cancer Drug Sales and Performance Analysis, 2014
6.4.2.2 RandD Performance Analysis, 2014
6.4.3 Recent MandA Activity: The Pfizer and AstraZeneca Saga

7. Ovarian Cancer Therapy: Developmental Pipelines 2015
7.1 Ovarian Cancer Phase III Candidates 2015
7.1.1 Niraparib (TESARO): Leading the PARP Inhibitors in the Pipeline
7.1.1.1 TESARO and Merck to Collaborate: Niraparib and Keytruda
7.1.2 Trebananib (Amgen/Takeda Pharmaceuticals): Misses Key Survival Measure in Phase III
7.1.3 Nintedanib (Boehringer Ingelheim): Triple Angiokinase Inhibitor
7.1.4 Recentin (AstraZeneca): Promising Results in Phase III
7.1.5 Rucaparib (Clovis Oncology): ARIEL2 and ARIEL3
7.1.6 Opaxio (CTI BioPharma): Biologically Enhanced Chemotherapeutic
7.1.7 Binimetinib (Array Biopharma): Expected Filing in 2016
7.1.8 Lurbinectedin (PharmaMar): Second-Generation Analogue of Yondelis (Trabectedin)
7.1.9 Virgil (Gradalis): Autologous Tumour Cell Vaccine
7.1.10 Farletuzumab (Eisai): Failure in Phase III
7.2 Ovarian Cancer Phase II Candidates 2015
7.2.1 CVac (Prima BioMed): MUC-1 Cancer Vaccine
7.2.2 SG2000 (Spirogen): Cytotoxic Technology Based on Pyrrolobenzodiazepines
7.2.3 Zoptarelin Doxorubicin (Aeterna Zentaris): Luteinising Hormone-Releasing Hormone (LHRH)
7.2.4 Reolysin (Oncolytics Biotech)
7.2.5 SGI110 (Astex Pharmaceuticals)
7.2.6 OvaRex (Quest PharmaTech)
7.2.7 Polyvalent Antigen-KLH Conjugate Vaccine (MabVax Therapeutics)
7.2.8 Motolimod (VentiRx Pharmaceuticals): Toll-Like Receptor 8 Agonist
7.2.9 Cyramza (Eli Lilly): Expanding Approved Indications
7.2.10 EGEN-001 (Celsion Corporation): IL-12 Immunotherapy
7.2.11 Ganetespib and Elesclomol (Synta Pharmaceuticals)
7.2.12 ENMD-2076 (CASI Pharmaceuticals)
7.2.13 GALE-301 (Galena Biopharma): Folate Binding Protein Vaccine
7.2.14 Epacadostat (Incyte Corporation): IDO1 Inhibitor
7.2.15 AZD1775 (AstraZeneca): WEE1 Kinase Inhibitor
7.2.16 Etirinotecan Pegol (Nektar Therapeutics): Promising Phase II Results
7.2.17 Linsitinib (Astellas Pharmaceuticals): Development Discontinued?
7.2.18 Afuresertib (GlaxoSmithKline): Multiple Oncology Indications
7.2.19 Zybrestat (OXiGENE): Vascular Disrupting Agent
7.2.20 Yervoy (Bristol-Myers Squibb)
7.2.21 Alisertib (Takeda Pharmaceuticals): Aurora A Kinase Inhibitor
7.2.22 Voxtalisib with Pimasertib (Sanofi and Merck Serono)
7.2.23 Eli Lilly's Phase II Ovarian Cancer Pipeline: LY2606368, Olaratumab and Ralimetinib
7.2.24 MK2206 (Merck and Co.): AKT Inhibitor
7.2.25 A6 Peptide (Angstrom Pharma)
7.2.26 Lifastuzumab Vedotin (Roche): Antibody Drug Conjugate
7.3 Ovarian Cancer Phase II Candidates 2015
7.3.1 VBL-111 (VBL Therapeutics): Anti-Angiogenic Agent
7.3.2 MEDI4736 (AstraZeneca)
7.3.3 OVax (AVAX Technologies)
7.3.4 ME-344 (Novogen)
7.3.5 DPX-Survivac and DPX-0907 (Immunovaccine): Two Novel Immunotherapies

8. Qualitative Analysis of the Ovarian Cancer Therapy Market 2015-2025
8.1 SWOT Analysis of the Ovarian Cancer Therapeutics Market
8.1.1 Strengths and Weaknesses of the Market
8.1.2 The Rising Incidence of Cancer
8.1.3 Drug Development Challenges
8.2 Opportunities and Threats for the Market
8.2.1 Advances in Research Open the Doors for Personalised Therapy
8.3 Regulations and Pricing Restrictions
8.4 STEP Analysis of the Ovarian Cancer Therapy Market
8.4.1 Social Factors: An Expanding Patient Population and Increasing Awareness
8.4.2 Technological Advances: DNA Sequencing of High-Grade Serous Ovarian Carcinoma
8.4.3 Economic Factors: Cost Cutting in the EU and the US
8.4.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Anti-Cancer Drugs?
8.5 Porter's Five Forces Analysis of the Ovarian Cancer Therapeutics Market
8.5.1 Rivalry Among Competitors
8.5.2 Threat of New Entrants
8.5.3 Power of Suppliers
8.5.4 Power of Buyers
8.5.5 Threat of Substitutes

9. Research Interviews
9.1 Interview with Prof. Dror Harats, CEO, VBL Therapeutics
9.1.1 Outlook for VB-111 in the Ovarian Cancer Market
9.1.2 Drivers and Restraints in the Ovarian Cancer Market
9.1.3 Trends in the Ovarian Cancer Market
9.1.4 Outlook for VBL Therapeutics in the Oncology Market
9.2 Interview with Mr Stuart Roberts, Global Head of Investor Relations, Prima BioMed
9.2.1 Outlook for CVac in the Ovarian Cancer Market
9.2.2 The Ovarian Cancer Market
9.2.3 Trends in the Ovarian Cancer Market
9.2.4 Outlook for Prima BioMed in the Oncology Market
9.3 Interview with a Representative of OXiGENE
9.3.1 Outlook for Zybrestat in the Ovarian Cancer Market
9.3.2 The Ovarian Cancer Market in 2015
9.3.3 Trends in the Ovarian Cancer Market, 2015-2025
9.3.4 Outlook for OXiGENE in the Oncology Market

10. Conclusions from the Research and Analysis
10.1 The World Ovarian Cancer Therapeutics Market in 2014
10.1.1 Leading National Markets to 2025
10.2 Trends in the Industry
10.2.1 Growing Interest in Personalised Therapy
10.2.2 Multiple Late-Stage Pipeline Drugs
10.3 Concluding Remarks

List of Tables
Table 1.1 Ovarian Cancer Therapy Market Forecast, 2014-2025
Table 1.2 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013 and 2014
Table 2.1 Types of Ovarian Cancer
Table 2.2 Stages of Ovarian Cancer
Table 2.3 Grades of Ovarian Cancer
Table 2.4 5-Year Prevalence for Ovarian Cancer by Region, 2012
Table 2.5 Incidence Rates for Ovarian Cancer by Country, 2012
Table 2.6 Cancer-Treating Agents: Chemotherapy, Immunotherapy, Targeted Therapy and Hormone Therapy, 2015
Table 3.1 The World Ovarian Cancer Therapy Market by Therapeutic Class: Revenues ($bn) and Market Shares (%), 2014
Table 3.2 The World Ovarian Cancer Therapy Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 3.3 The World Ovarian Cancer Therapy Market by Therapeutic Class: Revenues ($bn) and Market Shares (%), 2019 and 2025
Table 3.4 The World Ovarian Cancer Therapy Market by Therapeutic Class: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
Table 3.5 Global Ovarian Cancer Targeted Therapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
Table 3.6 Global Ovarian Cancer Chemotherapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
Table 3.7 Global Ovarian Cancer Immunotherapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
Table 3.8 Global Ovarian Cancer Hormone Therapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
Table 4.1 Avastin Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 4.2 Avastin Ovarian Cancer Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 4.3 Lynparza Ovarian Cancer Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 4.4 Yondelis Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 4.5 Yondelis Ovarian Cancer Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 5.1 Ovarian Cancer Therapy Market: Revenue ($bn) and Market Share (%) by Country, 2014
Table 5.2 Ovarian Cancer Drug Therapy Market: Revenue ($bn), AGR (%) and CAGR (%) by Country, 2015-2025
Table 5.3 Ovarian Cancer Therapy Revenue ($bn) and Market Share (%) by Country, 2014, 2019 and 2025
Table 5.4 US Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.5 EU5 Ovarian Cancer Drug Therapy Markets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.6 German Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.7 French Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.8 UK Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.9 Spanish Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.10 Italian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.11Japanese Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.12 Chinese Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.13 Indian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.14 Brazilian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.15 Ovarian Cancer Mortality Rate by Country, 2012
Table 5.16 Russian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 6.1 JandJ Revenue ($bn) and Revenue Share (%) by Sector, 2014
Table 6.2 JandJ Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 6.3 JandJ: Pharmaceutical Revenue ($bn) and Revenue Share (%) by Segment, 2013 and 2014
Table 6.4 JandJ: RandD Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
Table 6.5 Roche Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 6.6 Roche: Pharmaceutical Revenue ($bn) and Revenue Share (%) by Therapeutic Area, 2013 and 2014
Table 6.7 Roche: Anti-cancer Drug Revenues ($bn) and CAGR (%) by Therapeutic Area, 2012-2014
Table 6.8 Roche: Pharmaceutical RandD Expenses as a Percentage (%) of Company Revenue, 2012-2014
Table 6.9 Roche: Phase II Oncology Pipeline, 2015
Table 6.10 Roche: Phase III Oncology Pipeline, 2015
Table 6.11 AstraZeneca Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 6.12 AstraZeneca: Revenue ($bn) and Revenue Shares (%) by Therapeutic Area, 2013 and 2014
Table 6.13 AstraZeneca: Anti-cancer Drug Revenues ($bn) and CAGR (%), 2012-2014
Table 6.14 AstraZeneca: RandD Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
Table 6.15 AstraZeneca: Ovarian Cancer RandD Pipeline, 2014
Table 7.1 Selected Late-Phase Pipeline Candidates for Ovarian Cancer, 2015
Table 7.2 Selected Phase II Pipeline Candidates for Ovarian Cancer, 2015
Table 7.3 Selected Phase II Pipeline Candidates for Ovarian Cancer, 2015 (Continued)
Table 7.4 Selected Early Phase Pipeline Candidates for Ovarian Cancer, 2015
Table 8.1 Strengths and Weaknesses of the Ovarian Cancer Therapy Market, 2015-2025
Table 8.2 Opportunities and Threats Facing the Ovarian Cancer Therapy Market, 2015-2025
Table 8.3 Social, Technological, Economic and Political Forces Influencing the Ovarian Cancer Therapy Market (STEP Analysis), 2015-2025

List of Figures
Figure 2.1 5-Years Prevalence for Ovarian Cancer by Region, 2012
Figure 2.2 Incidence Rates for Ovarian Cancer by Country, 2012
Figure 3.1 the World Ovarian Cancer Therapy Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Figure 3.2 Ovarian Cancer Therapy Market: Drivers and Restraints, 2015-2025
Figure 3.3 Ovarian Cancer Therapy Market by Therapeutic Class, 2019
Figure 3.4 Ovarian Cancer Therapy Market by Therapeutic Class, 2025
Figure 3.5 The Global Ovarian Cancer Therapy Market by Therapeutic Class: Revenue Forecasts ($bn), 2015-2025
Figure 3.6 Global Ovarian Cancer Targeted Therapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.7 Ovarian Cancer Targeted Therapy Market: Drivers and Restraints, 2015-2025
Figure 3.8 Global Ovarian Cancer Chemotherapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.9 Ovarian Cancer Chemotherapy Market: Drivers and Restraints, 2015-2025
Figure 3.10 Global Ovarian Cancer Immunotherapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.11 Ovarian Cancer Immunotherapy Market: Drivers and Restraints, 2015-2025
Figure 3.12 Global Ovarian Cancer Hormone Therapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.13 Ovarian Cancer Hormone Therapy Market: Drivers and Restraints, 2015-2025
Figure 4.1 Avastin Revenue ($bn) and AGR (%), 2010-2014
Figure 4.2 Avastin Ovarian Cancer Revenue ($bn) Forecast, 2015-2025
Figure 4.3 Avastin: Drivers and Restraints, 2015-2025
Figure 4.4 Lynparza Ovarian Cancer Revenue ($bn) Forecast, 2015-2025
Figure 4.5 Lynparza: Drivers and Restraints, 2015-2025
Figure 4.6 Yondelis Revenue ($bn) and AGR (%), 2010-2014
Figure 4.7 Yondelis Ovarian Cancer Revenue ($bn) Forecast, 2015-2025
Figure 4.8 Yondelis: Drivers and Restraints, 2015-2025
Figure 5.1 Ovarian Cancer Drug Therapy Market Share (%) by Country, 2014
Figure 5.2 Developed National Markets: Drivers and Restraints, 2015-2025
Figure 5.3 Emerging National Markets: Drivers and Restraints, 2015-2025
Figure 5.4 Ovarian Cancer Therapy Market Share (%) by Country, 2019
Figure 5.5 Ovarian Cancer Therapy Market Share (%) by Country, 2025
Figure 5.6 US Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.7 EU5 Ovarian Cancer Therapy Markets: Revenue ($bn) Forecasts, 2015-2025
Figure 5.8 German Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.9 French Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.10 UK Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.11 Spanish Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.12 Italian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.13 Japanese Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.14 Chinese Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.15 Indian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.16 Brazilian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.17 Ovarian Cancer Mortality Rate by Country, 2012
Figure 5.18 Russian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 6.1 JandJ Revenue Share (%) by Sector, 2014
Figure 6.2 JandJ Historical Revenue ($bn) and AGR (%), 2010-2014
Figure 6.3 JandJ: Revenue Share (%) by Segment, 2014
Figure 6.4 JandJ: RandD Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
Figure 6.5 Roche Historical Revenue ($bn) and AGR (%), 2010-2014
Figure 6.6 Roche: Pharmaceutical Revenue Share (%) by Segment, 2014
Figure 6.7 Roche: Anti-cancer Drug Revenue Share (%), 2014
Figure 6.8 Roche: Pharmaceutical RandD Expenses as a Percentage (%) of Company Revenue, 2012-2014
Figure 6.9 AstraZeneca Historical Revenue ($bn) and AGR (%), 2010-2014
Figure 6.10 AstraZeneca: Revenue ($bn) by Therapeutic Area, 2013 and 2014
Figure 6.11 AstraZeneca: Revenue Share (%) by Therapeutic Area, 2014
Figure 6.12 AstraZeneca: Anti-cancer Drugs Revenue Share (%) by Drug, 2014
Figure 6.13 AstraZeneca: RandD Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
Figure 8.1 Porter's Five Forces Analysis of the Ovarian Cancer Drug Therapy Market, 2015-2025
Figure 10.1 Ovarian Cancer Therapy Market: Revenue Shares ($bn) by Drug, 2014-2025
Figure 10.2 Ovarian Cancer Therapy Market Revenue ($bn) by Country, 2014, 2019 and 2025

Companies Listed
AbbVie
Actavis
Advaxis
Aeterna Zentaris
Alios BioPharma (part of JandJ)
Almirall
American Cancer Society
American Society of Clinical Oncology
Amgen
Angstrom Pharma
Array BipPharma
Astellas Pharma
Astex Pharmaceuticals
AstraZeneca
Australia and New Zealand Gynecological Oncology Group (ANZGOG)
Autorita Garante della Concorrenza e del Mercato (Italian Competition Authority)
Auven Therapeutics
AVAX Technologies
Baxter Healthcare
Boehringer Ingelheim
Bristol-Myers Squibb
Busto Arisizio Hospital [Italy]
Cancer Research Institute
Cancer Research UK
Cancer Treatment Centers of America
CASI Pharmaceuticals
Celgene
Cell Therapeutics
Celsion Corporation
Cerulean Pharma
Chiba University Hospital
Clovis Oncology
CTI BioPharma (formerly Cell Therapeutics)
Eisai
Eli Lilly
ENGOT
EntreMed (now CASI Pharmaceuticals)
European Commission (EC)
Expression Genetics
Facing Our Risk of Cancer Empowered (FORCE)
Food and Drug Administration [US]
Fox Chase Cancer Center
Fresenius Biotech North America
Galena Biopharma
GCIG
Genia (part of Roche)
Genentech
GlaxoSmithKline
Gradalis
Grupo Español de Investigación en Cáncer de Ovario (GEICO)
Gynecologic Oncology Group
Immunovaccine
Immutep
Incyte
Indiana University School of Medicine
InterMune (part of Roche)
International Agency for Research on Cancer (IARC)
International Gynecologic Cancer Society (IGCS)
Janssen Biotech (part of Janssen Pharmaceutical Companies)
Janssen Pharmaceutical (part of JandJ)
Janssen Products (part of Janssen Pharmaceutical Companies)
Jiangsu Hengrui Med
Johnson and Johnson (JandJ)
Jubilant Biosys
Ludwig Institute for Cancer Research
MabVax Therapeutics
Marshall Edwards (now MEI Pharma)
Massachusetts General Hospital
McGill University
Medical Research Council [UK]
Medical University Innsbruck
MedImmune (part of AstraZeneca)
MEI Pharma (part of Novogen)
Memorial Sloan-Kettering Cancer Center
Menarini Group
Merck and Co.
Morphotek, Inc. (part of Eisai)
Myriad Genetics
National Cancer Institute [US]
National Health and Medical Research Council [Australia]
National Health Service (NHS) [UK]
NCIC Clinical Trials Group
National Institute for Health and Care Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
National Institutes of Health Clinical Center (NIHCC) [US]
Nektar Therapeutics
Neopharm Group
Nordic Society for Oncology
Novartis
Novogen
NRG Oncology
OBI Pharma
Oncolytics Biotech
Onconova Therapeutics
Orion Genomics
OXiGENE
Peter MacCallum Cancer Centre
PharmaMar (part of Zeltia Group)
Poniard Pharmaceuticals
Prima BioMed
Quest PharmaTech
Roche
Roxane
Sandoz (part of Novartis)
Sanofi
Santaris (part of Roche)
SCRI Development Innovations
Seragon Pharmaceuticals (part of Roche)
Society of Gynecologic Oncology
Spirogen
Stanford University
Sunesis Pharmaceuticals
Surveillance, Epidemiology and End Results Program (SEER) [US]
Synta Pharmaceuticals
Taiho Pharmaceutical
Takeda Pharmaceuticals
TESARO
University College London
University of Queensland's Institute for Molecular Biosciences (IMB)
Vascular Biogenics Ltd (VBL Therapeutics)
VBL Therapeutics
VentiRx Pharmaceuticals
Westmead Millennium Institute for Medical Research
World Cancer Research Fund International
Worldwide Cancer Research
Zeltia Group
Zybrestat

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.